Top Markets
#1 Black Phoenix Black Phoenix +167.06%
#2 Islamic Coin Islamic Coin +158.25%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +38.72%
#5 Test Test +21.35%
#6 Cryptopia Cryptopia +20.92%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.45%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +12.43%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +9.97%
#10 stake.link stake.link +9.30%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Nanomix Corporation Nanomix Corporation

Nanomix Corporation

NNMX
Classement en actions #41810
Boston Therapeutics, Inc. focuses on the discovery, production, and... Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
Prix de l'action
$0.0002
Dernière synchronisation: 2025-04-08
Capitalisation boursière
$9.80K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Nanomix Corporation (NNMX)

Catégorie

Healthcare
Bénéfices pour Nanomix Corporation (NNMX)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Nanomix Corporation, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Nanomix Corporation de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
$7.51B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
$5.15B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
$5.56B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
$3.86B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
$1.42B -
US